Ajanta Pharma share price

Balanced risk
  • 40%Low risk
  • 40%Moderate risk
  • 40%Balanced risk
  • 40%High risk
  • 40%Extreme risk
  • 2,673.10(-0.40%)
    April 23, 2025 15:29:46 PM IST
    • NSE
    • BSE
  • Vol : 65.83K (NSE + BSE)
    Last 20 day avg : 142.27 K

Ajanta Pharma is trading -0.40% lower at Rs 2,673.10 as compared to its last closing price. Ajanta Pharma has been trading in the price range of 2,737.95 & 2,659.00. Ajanta Pharma has given -8.63% in this year & 8.46% in the last 5 days. Ajanta Pharma has TTM P/E ratio 41.00 as compared to the sector P/E of 28.79.There are 10 analysts who have initiated coverage on Ajanta Pharma. There are 4 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 232.88 Crores in its last quarter.Listed peers of Ajanta Pharma include Ipca Laboratories (1.23%), Laurus Labs (-0.18%), Ajanta Pharma (-0.40%).The Mutual Fund holding in Ajanta Pharma was at 15.13% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Ajanta Pharma was at 8.86% in 31 Mar 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Apr 23, 2025, 11:01 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    1.05
    Inline with the industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    9.46
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    37.49
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    4.18
    Indicates overvaluation
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.41
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.01
    Lower than industry
Price range
Day Range
Lowest
2,659.00
Highest
2,737.95
52 week range
Lowest
2,022.05
Highest
3,485.75
Ajanta Pharma Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in December quarter by 3.71% from Rs 1146.13 crore to Rs 1105.15 crore, year-on-year
    • financial-insightsThe company has grown its December quarter profit by 10.88% from Rs 210.03 crore to Rs 232.88 crore, year-on-year
    • financial-insightsThe debt to equity of the company is lower than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Ajanta Pharma Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 2,877.78
  • R2
  • 3,137.07
  • R3
  • 3,564.93
Pivot2,449.92
  • S1
  • 2,190.63
  • S2
  • 1,762.77
  • S3
  • 1,503.48
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Ajanta Pharma Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Ipca Laboratories
Bullish
1,462.001.2337,157.6955.075.70.289.80
Laurus Labs
Bullish
650.45-0.1835,075.68213.428.40.1220.93
Ajanta Pharma
Neutral
2,673.10-0.4033,453.5641.249.462.020.66
Suven Pharmaceuticals
Bullish
1,201.15-2.5930,731.01101.0814.92-1.04
Piramal Pharma
Bullish
223.65-0.4029,650.36479.903.690.0532.89
Ajanta Pharma Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Ajanta Pharma is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPledged found - Promoter(s) have pledged 12.61% of shares.
    • InsightsPromoter(s) have increased pledged shares to 11.17% from 12.61% earlier.
    • InsightsPromoter(s) holds a high stake in the company at 66.26%
    • InsightsPromoter(s) have decreased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 0.40 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.24 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    NJ Flexi Cap Fund Regular Growth
    NA
    • Amount Invested (Cr.) 114.84
    • % of AUM 5.66
    UTI Healthcare Fund Regular Plan Growth
    NA
    • Amount Invested (Cr.) 45.88
    • % of AUM 4.40
    Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 33.92
    • % of AUM 4.16
    NJ ELSS Tax Saver Scheme Regular Growth
    NA
    • Amount Invested (Cr.) 9.34
    • % of AUM 3.77
    Samco Flexi Cap Fund Regular Growth
    1/5
    • Amount Invested (Cr.) 15.38
    • % of AUM 3.43
    Ajanta Pharma Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-01-30Quarterly Results
    2024-10-28Quarterly Results
    2024-07-30Quarterly Results
    2024-05-02Audited Results & Buy Back of Shares
    2024-01-31Quarterly Results & 2nd Interim Dividend
    About the company Ajanta Pharma
    • IndustryBiotechnology & Drugs
    • ISININE031B01049
    • BSE Code532331
    • NSE CodeAJANTPHARM
    Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
    • Management Info
    • Madhusudan AgrawalExecutive Vice Chairman of the Board
    • Arvind AgrawalChief Financial Officer
    • Gaurang ShahVice President - Legal, Company Secretary
    • Rajesh AgrawalJoint Managing Director, Executive Director
    • Yogesh AgrawalManaging Director, Executive Director
    Ajanta Pharma Share Price FAQs

    Ajanta Pharma is trading at 2673.10 as on Wed Apr 23 2025 09:59:46. This is -0.40% lower as compared to its previous closing price of 2683.95.

    The market capitalization of Ajanta Pharma is 33453.56 Cr as on Wed Apr 23 2025 09:59:46.

    The average broker rating on Ajanta Pharma is Buy. The breakup of analyst rating is given below -

    • 4 analysts have given a strong buy rating
    • 4 analysts have given a buy rating
    • 0.00 analysts have given a hold rating
    • 1 analysts have given a sell rating
    • 1 analysts have given a strong sell rating

    The 52 wk high for Ajanta Pharma is 3485.75 whereas the 52 wk low is 2022.05

    Ajanta Pharma can be analyzed on the following key metrics -

    • TTM P/E: 41.00
    • Sector P/E: 28.79
    • Dividend Yield: 1.05%
    • D/E ratio: -

    Ajanta Pharma reported a net profit of 816.17 Cr in 2024.

    The Mutual Fund Shareholding was 15.13% at the end of 31 Mar 2025.